Biosimilar Uptake in Medicare Advantage vs Traditional Medicare
Steven Kozlowski, Andrew Kwist, Rowan McEvoy, Nirabh Koirala, Yoganand Chillarige, Jeffrey A. Kelman, David J. Graham · 2023
Read Biosimilar Uptake in Medicare Advantage vs Traditional Medicare by Steven Kozlowski, Andrew Kwist, Rowan McEvoy, Nirabh Koirala, Yoganand Chillarige, Jeffrey A. Kelman, David J. Graham (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10755621.txt.
Description
Steven Kozlowski and co-authors compare uptake of biosimilar drugs between two forms of Medicare in this 2023 study. Biosimilars are near copies of costly biologic drugs and can widen access while cutting cost. Forty were approved in the United States by early 2023. Managed Medicare plans have tools, like prior approval, that may push use toward cheaper options.
Using claims and encounter data from 2015 to 2022, the team tracked twenty biosimilars across seven product types. Uptake ran higher in Medicare Advantage than in traditional Medicare for six of the seven types. The typical edge was about thirty percent higher share. One cancer drug went the other way, and its case is examined closely. The study maps how plan design shapes the spread of lower-cost drug copies.
Catalog record
| CREATOR | Steven Kozlowski, Andrew Kwist, Rowan McEvoy, Nirabh Koirala, Yoganand Chillarige, Jeffrey A. Kelman, David J. Graham |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 6 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |